Latest & greatest articles for simvastatin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on simvastatin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on simvastatin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for simvastatin

1. Simvastatin

Simvastatin Top results for simvastatin - Trip Database or use your Google+ account Liberating the literature My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing (...) the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for simvastatin The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines

Trip Latest and Greatest2018

2. Simvastatin to reduce pulmonary dysfunction in patients with acute respiratory distress syndrome: the HARP-2 RCT

Simvastatin to reduce pulmonary dysfunction in patients with acute respiratory distress syndrome: the HARP-2 RCT Simvastatin to reduce pulmonary dysfunction in patients with acute respiratory distress syndrome: the HARP-2 RCT Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find (...) the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> {{metadata.Title}} {{metadata.Headline}} This study showed that simvastatin did not increase the number of ventilator-free days or improve mortality in patients with acute respiratory distress syndrome. {{author}} {{($index , , , , , , , , , , , , & . Daniel F McAuley 1, 2, 3, * , John G Laffey 4 , Cecilia M O’Kane 1 , Gavin D Perkins 5, 6 , Brian Mullan 2 , Thomas J Trinder 7 , Paul Johnston 8 , Phillip A Hopkins 9 , Andrew J

NIHR HTA programme2018

3. The Impact of US FDA and Health Canada Warnings Related to the Safety of High-dose Simvastatin

The Impact of US FDA and Health Canada Warnings Related to the Safety of High-dose Simvastatin 28956294 2018 11 13 2199-1154 4 4 2017 Dec Drugs - real world outcomes Drugs Real World Outcomes The Impact of US FDA and Health Canada Warnings Related to the Safety of High-dose Simvastatin. 215-223 10.1007/s40801-017-0116-7 Between 2010 and 2012, the US Food and Drug Administration and Health Canada issued warnings to healthcare professionals emphasizing the increased risk of muscle problems (...) with high-dose simvastatin. To measure the impact of the Health Canada safety warning regarding dose-dependent adverse effects of simvastatin on prescribing of low, medium, and high doses of simvastatin. An interrupted time-series design was used to evaluate the impact of a Health Canada safety warning on 7 November 2012 regarding the safety of high-dose simvastatin. Monthly prescription records were analyzed for beneficiaries of the Nova Scotia Seniors' Pharmacare Program aged 65 years or older who had

Drugs - real world outcomes2017 Full Text: Link to full Text with Trip Pro

4. Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trial

Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trial 28600189 2017 06 10 2017 06 10 1474-4465 2017 Jun 06 The Lancet. Neurology Lancet Neurol Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS (...) -STAT randomised, placebo-controlled trial. S1474-4422(17)30113-8 10.1016/S1474-4422(17)30113-8 In the 24-month MS-STAT phase 2 trial, we showed that high-dose simvastatin significantly reduced the annualised rate of whole brain atrophy in patients with secondary progressive multiple sclerosis (SPMS). We now describe the results of the MS-STAT cognitive substudy, in which we investigated the treatment effect on cognitive, neuropsychiatric, and health-related quality-of-life (HRQoL) outcome measures

EvidenceUpdates2017

5. Addition of Simvastatin to Standard Therapy for the Prevention of Variceal Rebleeding Does Not Reduce Rebleeding but Increases Survival in Patients With Cirrhosis

Addition of Simvastatin to Standard Therapy for the Prevention of Variceal Rebleeding Does Not Reduce Rebleeding but Increases Survival in Patients With Cirrhosis 26774179 2016 04 24 2017 03 28 2017 04 18 1528-0012 150 5 2016 05 Gastroenterology Gastroenterology Addition of Simvastatin to Standard Therapy for the Prevention of Variceal Rebleeding Does Not Reduce Rebleeding but Increases Survival in Patients With Cirrhosis. 1160-1170.e3 10.1053/j.gastro.2016.01.004 S0016-5085(16)00043-3 (...) The combination of β-blockers and band ligation is the standard approach to prevent variceal rebleeding, but bleeding recurs and mortality is high. The lipid-lowering drug simvastatin decreases portal pressure, improves hepatocellular function, and might reduce liver fibrosis. We assessed whether adding simvastatin to standard therapy could reduce rebleeding and death after variceal bleeding in patients with cirrhosis. We performed a multicenter, double-blind, parallel trial of 158 patients with cirrhosis

EvidenceUpdates2016

6. Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP)

Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP) 26597925 2016 03 25 2016 08 01 2017 03 24 1523-6838 67 4 2016 Apr American journal of kidney diseases : the official journal of the National Kidney Foundation Am. J. Kidney Dis. Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP). 576-84 10.1053/j.ajkd (...) .2015.09.020 S0272-6386(15)01251-2 Simvastatin, 20mg, plus ezetimibe, 10mg, daily (simvastatin plus ezetimibe) reduced major atherosclerotic events in patients with moderate to severe chronic kidney disease (CKD) in the Study of Heart and Renal Protection (SHARP), but its cost-effectiveness is unknown. Cost-effectiveness of simvastatin plus ezetimibe in SHARP, a randomized controlled trial. 9,270 patients with CKD randomly assigned to simvastatin plus ezetimibe versus placebo; participants in categories

EvidenceUpdates2016

7. Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT

Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT 26330412 2015 09 29 2016 01 05 2016 07 28 1524-4539 132 13 2015 Sep 29 Circulation Circulation Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better (...) outcomes in IMPROVE-IT. 1224-33 10.1161/CIRCULATIONAHA.115.018381 Statins lower low-density lipoprotein cholesterol (LDL-C) and high-sensitivity C-reactive protein (hs-CRP); addition of ezetimibe to statins further reduces LDL-C and hs-CRP. An analysis of the relationship between achieved LDL-C and hs-CRP targets and outcomes for simvastatin and ezetimibe/simvastatin was prespecified in Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT). The IMPROVE-IT trial randomly

EvidenceUpdates2015

8. High-dose atorvastatin is superior to moderate-dose simvastatin in preventing peripheral arterial disease

High-dose atorvastatin is superior to moderate-dose simvastatin in preventing peripheral arterial disease 25595417 2015 02 14 2015 05 11 2015 11 19 1468-201X 101 5 2015 Mar Heart (British Cardiac Society) Heart High-dose atorvastatin is superior to moderate-dose simvastatin in preventing peripheral arterial disease. 356-62 10.1136/heartjnl-2014-306906 To study whether high-dose versus usual-dose statin treatment reduces the incidence of peripheral artery disease (PAD) and what is the effect (...) of high-dose statin treatment on cardiovascular disease (CVD) outcome in patients with PAD. In the Incremental Decrease in End Points Through Aggressive Lipid Lowering trial, 8888 post-myocardial infarction patients were randomised to high-dose or usual-dose statin therapy (atorvastatin 80 mg/day vs simvastatin 20-40 mg/day). We investigated the effect of high-dose versus usual-dose statins on the pre-specified outcome PAD incidence, and additionally performed a posthoc analysis of the efficacy

EvidenceUpdates2015

9. Simvastatin in the Acute Respiratory Distress Syndrome

Simvastatin in the Acute Respiratory Distress Syndrome PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

PedsCCM Evidence-Based Journal Club2014

10. Simvastatin in the acute respiratory distress syndrome.

Simvastatin in the acute respiratory distress syndrome. 25268516 2014 10 30 2014 11 07 2016 12 15 1533-4406 371 18 2014 Oct 30 The New England journal of medicine N. Engl. J. Med. Simvastatin in the acute respiratory distress syndrome. 1695-703 10.1056/NEJMoa1403285 Studies in animals and in vitro and phase 2 studies in humans suggest that statins may be beneficial in the treatment of the acute respiratory distress syndrome (ARDS). This study tested the hypothesis that treatment (...) with simvastatin would improve clinical outcomes in patients with ARDS. In this multicenter, double-blind clinical trial, we randomly assigned (in a 1:1 ratio) patients with an onset of ARDS within the previous 48 hours to receive enteral simvastatin at a dose of 80 mg or placebo once daily for a maximum of 28 days. The primary outcome was the number of ventilator-free days to day 28. Secondary outcomes included the number of days free of nonpulmonary organ failure to day 28, mortality at 28 days, and safety

NEJM2014

11. Simvastatin in the acute respiratory distress syndrome.

Simvastatin in the acute respiratory distress syndrome. BACKGROUND: Studies in animals and in vitro and phase 2 studies in humans suggest that statins may be beneficial in the treatment of the acute respiratory distress syndrome (ARDS). This study tested the hypothesis that treatment with simvastatin would improve clinical outcomes in patients with ARDS. METHODS: In this multicenter, double-blind clinical trial, we randomly assigned (in a 1:1 ratio) patients with an onset of ARDS within the (...) previous 48 hours to receive enteral simvastatin at a dose of 80 mg or placebo once daily for a maximum of 28 days. The primary outcome was the number of ventilator-free days to day 28. Secondary outcomes included the number of days free of nonpulmonary organ failure to day 28, mortality at 28 days, and safety. RESULTS: The study recruited 540 patients, with 259 patients assigned to simvastatin and 281 to placebo. The groups were well matched with respect to demographic and baseline physiological

NEJM2014

12. Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial.

Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. BACKGROUND: Secondary progressive multiple sclerosis, for which no satisfactory treatment presently exists, accounts for most of the disability in patients with multiple sclerosis. Simvastatin, which is widely used for treatment of vascular disease, with its excellent safety profile, has immunomodulatory and neuroprotective (...) properties that could make it an appealing candidate drug for patients with secondary progressive multiple sclerosis. METHODS: We undertook a double-blind, controlled trial between Jan 28, 2008, and Nov 4, 2011, at three neuroscience centres in the UK. Patients aged 18-65 years with secondary progressive multiple sclerosis were randomly assigned (1:1), by a centralised web-based service with a block size of eight, to receive either 80 mg of simvastatin or placebo. Patients, treating physicians

Lancet2014

13. Simvastatin for the prevention of exacerbations in moderate-to-severe COPD.

Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. BACKGROUND: Retrospective studies have shown that statins decrease the rate and severity of exacerbations, the rate of hospitalization, and mortality in chronic obstructive pulmonary disease (COPD). We prospectively studied the efficacy of simvastatin in preventing exacerbations in a large, multicenter, randomized trial. METHODS: We designed the Prospective Randomized Placebo-Controlled Trial of Simvastatin (...) in the Prevention of COPD Exacerbations (STATCOPE) as a randomized, controlled trial of simvastatin (at a daily dose of 40 mg) versus placebo, with annual exacerbation rates as the primary outcome. Patients were eligible if they were 40 to 80 years of age, had COPD (defined by a forced expiratory volume in 1 second [FEV1] of less than 80% and a ratio of FEV1 to forced vital capacity of less than 70%), and had a smoking history of 10 or more pack-years, were receiving supplemental oxygen or treatment

NEJM2014

14. Simvastatin for the Prevention of Exacerbations in Moderate-to-Severe COPD.

Simvastatin for the Prevention of Exacerbations in Moderate-to-Severe COPD. 24836125 2014 06 06 2014 06 10 2017 02 20 1533-4406 370 23 2014 Jun 05 The New England journal of medicine N. Engl. J. Med. Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. 2201-10 10.1056/NEJMoa1403086 Retrospective studies have shown that statins decrease the rate and severity of exacerbations, the rate of hospitalization, and mortality in chronic obstructive pulmonary disease (COPD). We (...) prospectively studied the efficacy of simvastatin in preventing exacerbations in a large, multicenter, randomized trial. We designed the Prospective Randomized Placebo-Controlled Trial of Simvastatin in the Prevention of COPD Exacerbations (STATCOPE) as a randomized, controlled trial of simvastatin (at a daily dose of 40 mg) versus placebo, with annual exacerbation rates as the primary outcome. Patients were eligible if they were 40 to 80 years of age, had COPD (defined by a forced expiratory volume in 1

NEJM2014 Full Text: Link to full Text with Trip Pro

15. Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial.

Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. 24655729 2014 06 30 2014 07 09 2016 11 22 1474-547X 383 9936 2014 Jun 28 Lancet (London, England) Lancet Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. 2213-21 10.1016/S0140-6736(13)62242-4 S0140-6736(13)62242 (...) -4 Secondary progressive multiple sclerosis, for which no satisfactory treatment presently exists, accounts for most of the disability in patients with multiple sclerosis. Simvastatin, which is widely used for treatment of vascular disease, with its excellent safety profile, has immunomodulatory and neuroprotective properties that could make it an appealing candidate drug for patients with secondary progressive multiple sclerosis. We undertook a double-blind, controlled trial between Jan 28, 2008

Lancet2014

17. Ezetimibe and simvastatin (Inegy) for reduction of cardiovascular risk in coronary heart disease

Ezetimibe and simvastatin (Inegy) for reduction of cardiovascular risk in coronary heart disease Ezetimibe and simvastatin (Inegy) for reduction of cardiovascular risk in coronary heart disease Ezetimibe and simvastatin (Inegy) for reduction of cardiovascular risk in coronary heart disease NIHR HSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database (...) . Citation NIHR HSC. Ezetimibe and simvastatin (Inegy) for reduction of cardiovascular risk in coronary heart disease. Birmingham: NIHR Horizon Scanning Centre (NIHR HSC). Horizon Scanning Review. 2013 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Azetidines; Coronary Diseases; Drug Combinations; Simvastatin Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence The NIHR Horizon Scanning

Health Technology Assessment (HTA) Database.2013

19. Cost-effectiveness of rosuvastatin in comparison with generic atorvastatin and simvastatin in a Swedish population at high risk of cardiovascular events

Cost-effectiveness of rosuvastatin in comparison with generic atorvastatin and simvastatin in a Swedish population at high risk of cardiovascular events Cost-effectiveness of rosuvastatin in comparison with generic atorvastatin and simvastatin in a Swedish population at high risk of cardiovascular events Cost-effectiveness of rosuvastatin in comparison with generic atorvastatin and simvastatin in a Swedish population at high risk of cardiovascular events Gandhi SK, Jensen MM, Fox KM, Smolen L (...) concluded that rosuvastatin was cost-effective, over a lifetime, compared with generic simvastatin or atorvastatin. The lack of detailed reporting and the highlighted limitations to this study mean that the authors’ conclusions should be considered with caution. Type of economic evaluation Cost-effectiveness analysis, cost-utility analysis Study objective This study evaluated the long-term cost-effectiveness of alternative statin therapies in Swedish patients with a high risk of cardiovascular events

NHS Economic Evaluation Database.2012

20. Economic evaluation of ezetimibe combined with simvastatin for the treatment of primary hypercholesterolaemia

Economic evaluation of ezetimibe combined with simvastatin for the treatment of primary hypercholesterolaemia Economic evaluation of ezetimibe combined with simvastatin for the treatment of primary hypercholesterolaemia Economic evaluation of ezetimibe combined with simvastatin for the treatment of primary hypercholesterolaemia van Nooten F, Davies GM, Jukema JW, Liem AH, Yap E, Hu XH Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion (...) on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study aimed to assess the cost-effectiveness of ezetimibe in combination with simvastatin, for the treatment of patients with primary hypercholesterolaemia. The authors concluded that ezetimibe plus simvastatin appeared to be cost-effective for these patients who had not achieved

NHS Economic Evaluation Database.2012